Kwadwo Owusu Akuffo1, Stephen Beatty1, Tunde Peto2, Jim Stack1, Jim Stringham3, David Kelly1, Irene Leung4, Laura Corcoran1, John M Nolan1. 1. Macular Pigment Research Group, Nutrition Research Centre Ireland, School of Health Sciences, Waterford Institute of Technology, Waterford, Ireland. 2. Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom. 3. Nutritional Neuroscience Laboratory, Department of Physiology and Pharmacology, University of Georgia, Athens, Georgia, United States. 4. NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom.
Abstract
Purpose: The purpose of this study was to evaluate the impact of supplemental macular carotenoids (including versus not including meso-zeaxanthin) in combination with coantioxidants on visual function in patients with nonadvanced age-related macular degeneration. Methods: In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye Disease Study 2 formulation with alow dose [25 mg] of zinc and an addition of 10 mg meso-zeaxanthin; n = 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61). Visual function was assessed using best-corrected visual acuity, contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading performance, and the National Eye Institute Visual Function Questionnaire-25. Macular pigment was measured using customized heterochromatic flicker photometry. Results: There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881). Statistically significant improvements in several secondary outcome visual function measures (letter CS at 1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at 1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time; retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05, for all), and were statistically comparable between interventions (P > 0.05, for all). Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05). Conclusions: Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
RCT Entities:
Purpose: The purpose of this study was to evaluate the impact of supplemental macular carotenoids (including versus not including meso-zeaxanthin) in combination with coantioxidants on visual function in patients with nonadvanced age-related macular degeneration. Methods: In this study, 121 participants were randomly assigned to group 1 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso-zeaxanthin; n = 60) or group 2 (Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61). Visual function was assessed using best-corrected visual acuity, contrast sensitivity (CS), glare disability, retinal straylight, photostress recovery time, reading performance, and the National Eye Institute Visual Function Questionnaire-25. Macular pigment was measured using customized heterochromatic flicker photometry. Results: There was a statistically significant improvement in the primary outcome measure (letter CS at 6 cycles per degree [6 cpd]) over time (P = 0.013), and this observed improvement was statistically comparable between interventions (P = 0.881). Statistically significant improvements in several secondary outcome visual function measures (letter CS at 1.2 and 2.4 cpd; mesopic and photopic CS at all spatial frequencies; mesopic glare disability at 1.5, 3, and 6 cpd; photopic glare disability at 1.5, 3, 6, and 12 cpd; photostress recovery time; retinal straylight; mean and maximum reading speed) were also observed over time (P < 0.05, for all), and were statistically comparable between interventions (P > 0.05, for all). Statistically significant increases in macular pigment at all eccentricities were observed over time (P < 0.0005, for all), and the degree of augmentation was statistically comparable between interventions (P > 0.05). Conclusions: Antioxidant supplementation in patients with nonadvanced age-related macular degeneration results in significant increases in macular pigment and improvements in CS and other measures of visual function. (Clinical trial, http://www.isrctn.com/ISRCTN13894787).
Authors: Binxing Li; Gregory T Rognon; Ty Mattinson; Preejith P Vachali; Aruna Gorusupudi; Fu-Yen Chang; Arunkumar Ranganathan; Kelly Nelson; Evan W George; Jeanne M Frederick; Paul S Bernstein Journal: Arch Biochem Biophys Date: 2018-05-06 Impact factor: 4.013
Authors: Fábio B Daga; Nara G Ogata; Felipe A Medeiros; Rachel Moran; Jeffrey Morris; Linda M Zangwill; Robert N Weinreb; John M Nolan Journal: Invest Ophthalmol Vis Sci Date: 2018-09-04 Impact factor: 4.799
Authors: Deepayan Kar; Mark E Clark; Thomas A Swain; Gerald McGwin; Jason N Crosson; Cynthia Owsley; Kenneth R Sloan; Christine A Curcio Journal: Invest Ophthalmol Vis Sci Date: 2020-07-01 Impact factor: 4.799
Authors: Marina Green-Gomez; Paul S Bernstein; Christine A Curcio; Rachel Moran; Warren Roche; John M Nolan Journal: Transl Vis Sci Technol Date: 2019-12-18 Impact factor: 3.283
Authors: Divya Narayanan; John Rodriguez; Garrick Wallstrom; Donna Welch; Matthew Chapin; Paul Arrigg; Mark Abelson Journal: BMC Ophthalmol Date: 2020-10-22 Impact factor: 2.209
Authors: Marina Green-Gomez; Rachel Moran; James Stringham; Cesar Hernández-Alcaraz; Kenny Mendoza-Herrera; J Jans Fromow-Guerra; Alfonso Prado-Cabrero; John Nolan Journal: Invest Ophthalmol Vis Sci Date: 2021-07-01 Impact factor: 4.799